Sandbox:hudakarman: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) No edit summary |
Hudakarman (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{A}} | {{A}} | ||
{{CMG}} {{hudakarman}} | {{CMG}} {{hudakarman}} , {{Rana}}, {{Nuha}}, {{SumanthK}}, {{Dina}}, {{Samah}} | ||
Revision as of 23:55, 11 June 2020
Template:A Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Huda A. Karman, M.D. , Rana Aljebzi, MD[2], Nuha Al-Howthi, MD[3], Sumanth Khadke, MD[4], Template:Dina, Template:Samah
|
Disease Microchapters |
|
Treatment |
|---|
|
Case Studies |
.................................. ................................ ......................................
{{SK}} [1] it was doscovered by [2]
Table1
| Variant | Associated mutation |
|---|---|
Table2
| Variant | Associated mutation |
|---|---|
Table3
| A | B |
|---|---|
| C |
|
| E | F |
| |
| H | |
| |
| K | |
| |
| M | |
|
Table4
| Disease | Characteristics | Signs and Symptoms | Associated Conditions | Histopathology | Lab finding
& Other evaluation |
Prognosis |
|---|---|---|---|---|---|---|
| A |
|
|
|
|
|
|
CVS
CVS
vsd
ASD
Synonyms and keywords:
HEM has four main components, Preparedness, response, recovery, and mitigation. When we assess the development, the challenges, the setbacks, and progress of FEMA throughout history, we should look at the big picture and and also at the individual components. 1903:
References
- ↑ Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ (2009). "Type 2 diabetes in children and adolescents". Pediatr Diabetes. 10 Suppl 12: 17–32. doi:10.1111/j.1399-5448.2009.00584.x. PMID 19754615.
- ↑ Zenz S, Mader JK, Regittnig W, Brunner M, Korsatko S, Boulgaropoulos B; et al. (2018). "Impact of C-Peptide Status on the Response of Glucagon and Endogenous Glucose Production to Induced Hypoglycemia in T1DM". J Clin Endocrinol Metab. 103 (4): 1408–1417. doi:10.1210/jc.2017-01836. PMID 29408994.